Author(s): Teh LK, Bertilsson L
Abstract Share this page
Abstract CYP2D6 has received intense attention since the beginning of the pharmacogenetic era in the 1970s. This is because of its involvement in the metabolism of more than 25\% of the marketed drugs, the large geographical and inter-ethnic differences in the genetic polymorphism and possible drug-induced toxicity. Many interesting reviews have been published on CYP2D6 and this review aims to reinstate the importance of the genetic polymorphism of CYP2D6 in different populations as well as some clinical implications and important drug interactions.
This article was published in Drug Metab Pharmacokinet
and referenced in Journal of Pharmacogenomics & Pharmacoproteomics